Literature DB >> 8225313

A study of the association between schizophrenia and the dopamine D3 receptor gene.

S Nanko1, T Sasaki, R Fukuda, M Hattori, X Y Dai, H Kazamatsuri, S Kuwata, T Juji, M Gill.   

Abstract

A study of the genetic association between schizophrenia and a BalI polymorphism in exon 1 of the dopamine D3 (DRD3) gene, a candidate gene for schizophrenia, was conducted. The polymorphism was examined in 91 patients whose symptoms satisfied DSM-III-R for schizophrenia and 90 controls. There were no significant differences between the groups in allele frequencies or genotype counts. Contrary to a previous report, the patients were no more likely to be homozygous than controls. Moreover, no association with the presence of illness could be demonstrated when the patients were grouped according to sex, age of onset, history of admission to psychiatric institutions or positive family history.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8225313     DOI: 10.1007/bf01247330

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  7 in total

1.  Association between schizophrenia and homozygosity at the dopamine D3 receptor gene.

Authors:  M A Crocq; R Mant; P Asherson; J Williams; Y Hode; A Mayerova; D Collier; L Lannfelt; P Sokoloff; J C Schwartz
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

2.  [Gene cloning of human dopaminergic D3 receptor and identification of its chromosome].

Authors:  B Giros; M P Martres; P Sokoloff; J C Schwartz
Journal:  C R Acad Sci III       Date:  1990

Review 3.  Delineation of genetic predisposition to multifactorial disease: a general approach on the threshold of feasibility.

Authors:  J L Sobell; L L Heston; S S Sommer
Journal:  Genomics       Date:  1992-01       Impact factor: 5.736

4.  Chromosomal localization of the human D3 dopamine receptor gene.

Authors:  M Le Coniat; P Sokoloff; J Hillion; M P Martres; B Giros; C Pilon; J C Schwartz; R Berger
Journal:  Hum Genet       Date:  1991-09       Impact factor: 4.132

5.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.

Authors:  P Sokoloff; B Giros; M P Martres; M L Bouthenet; J C Schwartz
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

Review 6.  The current status of the dopamine hypothesis of schizophrenia.

Authors:  A Carlsson
Journal:  Neuropsychopharmacology       Date:  1988-09       Impact factor: 7.853

Review 7.  Brain dopamine receptors.

Authors:  P Seeman
Journal:  Pharmacol Rev       Date:  1980-09       Impact factor: 25.468

  7 in total
  6 in total

1.  A search for association between schizophrenia and dopamine-related alleles.

Authors:  E Jönsson; S Brené; T Geijer; L Terenius; A Tylec; M L Persson; G Sedvall
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

Review 2.  Molecular genetics of schizophrenia: past, present and future.

Authors:  Suman Prasad; Prachi Semwal; Smita Deshpande; Triptish Bhatia; V L Nimgaonkar; B K Thelma
Journal:  J Biosci       Date:  2002-02       Impact factor: 1.826

3.  Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia.

Authors:  S Shaikh; D A Collier; P C Sham; D Ball; K Aitchison; H Vallada; I Smith; M Gill; R W Kerwin
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

Review 4.  Genetics of schizophrenia: from animal models to clinical studies.

Authors:  Ridha Joober; Patricia Boksa; Chawki Benkelfat; Guy Rouleau
Journal:  J Psychiatry Neurosci       Date:  2002-09       Impact factor: 6.186

5.  Reappraisal of the role of the DRD3 gene in essential tremor.

Authors:  Marcia A Blair; Shaochun Ma; Fenna Phibbs; John Y Fang; Michael K Cooper; Thomas L Davis; Peter Hedera
Journal:  Parkinsonism Relat Disord       Date:  2008-03-03       Impact factor: 4.891

6.  No association between dopamine D3 receptor gene Ser9Gly polymorphism (rs6280) and risk of schizophrenia: an updated meta-analysis.

Authors:  Xing-Ling Qi; Jin-Feng Xuan; Jia-Xin Xing; Bao-Jie Wang; Jun Yao
Journal:  Neuropsychiatr Dis Treat       Date:  2017-11-23       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.